Rivus Pharmaceuticals enters a new development phase as CEO Jorge Bartolome outlines a shift toward late-stage clinical execution in MASH and broader cardiometabolic disease. The company advances its lead asset HU6 into Phase 3 planning while expanding its pipeline in
